Arca
Skip to content
Tools
Tools

Immunoglobulin A nephropathy

Drug research and approvals for immunoglobulin A nephropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 99 studies of immunoglobulin A nephropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 99
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 4
  • EU medicines: 2

Recruiting now

Newest posted first, of 99 recruiting on ClinicalTrials.gov ↗

How its trials ended

184 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 41 whose ending is known, 41% met their primary endpoint, 7% missed it and 51% stopped early.

  • Ongoing6636%
  • Completed, result not reported4927%
  • Status unknown2815%
  • Met its primary endpoint179%
  • Stopped: other or unclear84%
  • Stopped: sponsor or business decision74%
  • Stopped: enrollment or feasibility42%
  • Missed its primary endpoint32%
  • Stopped: lack of efficacy21%

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Oct 14, 2026A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of zigakibart in pediatric patients with primary…Zigakibart (FUB523)Novartis PharmaceuticalsPending
Aug 28, 2026A phase 3, open-label, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric participantsUltomiris [ravulizumab (ALXN1210)]AstraZeneca PharmaceuticalsPending
Dec 17, 2024A phase 2b, multicenter, open-label, single-arm trial to evaluate the impact of sibeprenlimab on kidney histopathology through repeat kidney biopsies in…Sibeprenlimab (VIS649)Otsuka HoldingsOngoing
Aug 20, 2024A phase 3, randomized, double-blind, placebo-controlled study of povetacicept in adults with immunoglobulin A nephropathy (RAINIER)Povetacicept injectionAlpine Immune SciencesOngoing
Mar 12, 2024A phase 3, double-blind, randomized, adaptive design study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin A…Ravulizumab (ALXN1210)AstraZeneca PharmaceuticalsOngoing
Jun 21, 2022A phase 3, multicenter, randomized, doubleblind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in…Sibeprenlimab (VIS649)Otsuka HoldingsClosed
Jun 16, 2022A phase 2/3, multicenter, open label trial to evaluate the long term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously in…Sibeprenlimab (VIS649)Otsuka HoldingsOngoing
Mar 10, 2020A multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy and safety of VIS649 in participants with…VIS649Visterra, IncOngoing
Feb 22, 2019A phase 2, randomized, double-blind, placebo-controlled study of cemdisiran in adult patients with iga nephropathyCemdisiran (ALN-CC5)Alnylam PharmaceuticalsClosed
May 18, 2018A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IGA) nephropathy…OMS721OmerosOngoing

FDA orphan designations

Approved first, then open designations, newest first
Sep 5, 2024FilspariTo slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progressionTravere Therapeutics, Inc.Approved
Dec 20, 2023TarpeyoTo reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progressionCalliditas Therapeutics ABApproved
Feb 17, 2023FilspariTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine…Travere Therapeutics, Inc.Approved
Dec 15, 2021TarpeyoTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine…Calliditas Therapeutics ABApproved
Aug 7, 2017BlisibimodTreatment of patients with immunoglobulin A nephropathyAnthera Pharmaceuticals, Inc.Designated
Aug 3, 2017Human monoclonal antibody inhibitor of mannan binding…Treatment of immunoglobulin A nephropathy (IgAN)Omeros CorporationDesignated
Apr 18, 2011Recombinant IgA protease of bacterium Heamophilus influenzaeTreatment of immunoglobulin A nephropathy (IgAN, Berger's disease).Shire Human Genetics TherapiesDesignated

Medicines authorised in the EU

Newest first
Apr 19, 2024FilspariSparsentan · orphanVifor FranceEMA ↗
Jul 15, 2022KinpeygoBudesonide · orphanStada Arzneimittel AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.